Unicycive Therapeutics Announced That The Peer-reviewed International Journal The American Journal Of Nephrology Has Published Results On The Phosphate Binding Capacity For Oxylanthanum Carbonate
Portfolio Pulse from Benzinga Newsdesk
Unicycive Therapeutics' investigational phosphate binding agent, oxylanthanum carbonate, has had its results published in the American Journal of Nephrology. The agent, which uses proprietary nanoparticle technology, is being developed as a treatment for hyperphosphatemia in chronic kidney disease patients on dialysis.
July 18, 2023 | 11:07 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Unicycive Therapeutics' investigational drug, oxylanthanum carbonate, has had its results published in a peer-reviewed journal. This could potentially increase investor confidence in the company's research and development capabilities.
The publication of the results of Unicycive's investigational drug in a peer-reviewed journal is a positive development. It validates the company's research and could potentially attract more investors. However, the drug is still in the investigational stage, and its commercial success is not guaranteed.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100